THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE
Anti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs. Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.); such patients ar...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2019-01-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223776437895168 |
|---|---|
| author | A. G. Samoylova E. I. Veselova O. V. Lovacheva G. D. Kaminsky |
| author_facet | A. G. Samoylova E. I. Veselova O. V. Lovacheva G. D. Kaminsky |
| author_sort | A. G. Samoylova |
| collection | DOAJ |
| description | Anti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs. Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.); such patients are treated for their main disease in addition to anti-tuberculosis chemotherapy. A large number of drugs used simultaneously in treatment regimens can reduce patient's adherence to treatment, deteriorate drug tolerance and increase the frequency of adverse reactions. Using slow-release drugs within treatment regimens is one of the ways to reduce polypragmasy. One of them is rifapentine, recommended in the Russian Federation for the treatment of latent tuberculosis infection in patients with HIV infection.The review presents information about the efficacy, tolerability and safety of rifapentine within treatment regimens for active and latent tuberculosis infection. |
| format | Article |
| id | doaj-art-ef6be59d87d6445785e4e42d03837cc7 |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2019-01-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-ef6be59d87d6445785e4e42d03837cc72025-08-20T02:05:49ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062019-01-019612556110.21292/2075-1230-2018-96-12-55-611204THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USEA. G. Samoylova0E. I. Veselova1O. V. Lovacheva2G. D. Kaminsky3National Medical Research Center of Phthisiopulmonology and Infectious DiseasesNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesAnti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs. Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.); such patients are treated for their main disease in addition to anti-tuberculosis chemotherapy. A large number of drugs used simultaneously in treatment regimens can reduce patient's adherence to treatment, deteriorate drug tolerance and increase the frequency of adverse reactions. Using slow-release drugs within treatment regimens is one of the ways to reduce polypragmasy. One of them is rifapentine, recommended in the Russian Federation for the treatment of latent tuberculosis infection in patients with HIV infection.The review presents information about the efficacy, tolerability and safety of rifapentine within treatment regimens for active and latent tuberculosis infection.https://www.tibl-journal.com/jour/article/view/1204rifapentineactive and latent tuberculous infectionanti-tuberculosis chemotherapy |
| spellingShingle | A. G. Samoylova E. I. Veselova O. V. Lovacheva G. D. Kaminsky THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE Туберкулез и болезни лёгких rifapentine active and latent tuberculous infection anti-tuberculosis chemotherapy |
| title | THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE |
| title_full | THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE |
| title_fullStr | THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE |
| title_full_unstemmed | THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE |
| title_short | THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE |
| title_sort | anti tuberculosis antibiotic of rifapentine perspectives of clinical use |
| topic | rifapentine active and latent tuberculous infection anti-tuberculosis chemotherapy |
| url | https://www.tibl-journal.com/jour/article/view/1204 |
| work_keys_str_mv | AT agsamoylova theantituberculosisantibioticofrifapentineperspectivesofclinicaluse AT eiveselova theantituberculosisantibioticofrifapentineperspectivesofclinicaluse AT ovlovacheva theantituberculosisantibioticofrifapentineperspectivesofclinicaluse AT gdkaminsky theantituberculosisantibioticofrifapentineperspectivesofclinicaluse AT agsamoylova antituberculosisantibioticofrifapentineperspectivesofclinicaluse AT eiveselova antituberculosisantibioticofrifapentineperspectivesofclinicaluse AT ovlovacheva antituberculosisantibioticofrifapentineperspectivesofclinicaluse AT gdkaminsky antituberculosisantibioticofrifapentineperspectivesofclinicaluse |